Even for those tested during adulthood, the robust recall of an individual with a GPV in, for example, PALB2 at 25–30 years for breast cancer surveillance, then again at 50 years of age regarding ovarian cancer risk management, requires careful coordination with inbuilt failsafes. This evidence concerns the gene PALB2 and breast cancer.